The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study

[1]  G. Filippatos,et al.  Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. , 2022, Journal of the American College of Cardiology.

[2]  P. Ponikowski,et al.  Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF , 2022, Circulation.

[3]  G. Santulli,et al.  Correlation of physical and cognitive impairment in diabetic and hypertensive frail older adults , 2022, Cardiovascular Diabetology.

[4]  Jin-fang Xu,et al.  Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS , 2021, Frontiers in Pharmacology.

[5]  D. Wexler,et al.  Association of Sodium-Glucose Cotransporter–2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes , 2021, JAMA network open.

[6]  N. Girerd.  Low Blood Pressure and Managing Drugs in HF: Where Do SGLT2 Inhibitors Stand? , 2021, Journal of the American College of Cardiology.

[7]  G. Chodick,et al.  Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence , 2021, Cardiovascular Diabetology.

[8]  D. Mauricio,et al.  Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia , 2021, Cardiovascular Diabetology.

[9]  X. Ye,et al.  Safety of SGLT2 Inhibitors: A Pharmacovigilance Study From 2015 to 2020 Based on FDA Adverse Event Report System Database , 2021 .

[10]  L. Ji,et al.  SGLT2 inhibitors and lower limb complications: an updated meta‐analysis , 2021, Cardiovascular Diabetology.

[11]  A. Avogaro,et al.  SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system , 2021, Cardiovascular Diabetology.

[12]  M. Roustit,et al.  Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. , 2021, Journal of clinical epidemiology.

[13]  G. Filippatos,et al.  Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function , 2020, Circulation.

[14]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[15]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[16]  S. Schneeweiss,et al.  Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study , 2020, BMJ.

[17]  Xin Sun,et al.  SGLT2 inhibitors and risk of diabetic ketoacidosis in patients with type 2 diabetes: systematic review and meta-analysis of randomized controlled trials. , 2020, Diabetes, obesity & metabolism.

[18]  Deepak L. Bhatt,et al.  Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study , 2019, Diabetes Care.

[19]  S. Schneeweiss,et al.  Association of Sodium-Glucose Cotransporter 2 Inhibitor Treatment With Risk of Hospitalization for Fournier Gangrene Among Men. , 2019, JAMA internal medicine.

[20]  B. Zinman,et al.  Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial. , 2019, Age and ageing.

[21]  A. Avogaro,et al.  Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors , 2019, BMJ Open Diabetes Research & Care.

[22]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[23]  D. O'Neal,et al.  SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission. , 2019, The Journal of clinical endocrinology and metabolism.

[24]  S. Schneeweiss,et al.  Fracture Risk After Initiation of Use of Canagliflozin , 2019, Annals of Internal Medicine.

[25]  C. Kortepeter,et al.  Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. , 2019, Annals of internal medicine.

[26]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[27]  Sonal Singh,et al.  Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes , 2018, JAMA internal medicine.

[28]  K. Lee,et al.  Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study , 2018, Cardiovascular Diabetology.

[29]  S. Arnold,et al.  Cardiovascular Outcomes and Mortality in Type 2 Diabetes with Associated Cardio-Renal-Metabolic Comorbidities , 2018, Diabetes.

[30]  A. Pariente,et al.  Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. , 2018, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[31]  M. Roustit,et al.  SGLT‐2 inhibitors and the risk of lower‐limb amputation: Is this a class effect? , 2018, Diabetes, obesity & metabolism.

[32]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[33]  S. Jabbour,et al.  Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials , 2017, Diabetes, obesity & metabolism.

[34]  B. Zinman,et al.  Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial , 2017, Diabetes Care.

[35]  Xin Sun,et al.  Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis , 2017, Scientific Reports.

[36]  A. Avogaro,et al.  SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System , 2017, Diabetologia.

[37]  G. Pazour,et al.  Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness , 2017, Scientific Reports.

[38]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[39]  N. Watts,et al.  Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. , 2016, The Journal of clinical endocrinology and metabolism.

[40]  N. Shah,et al.  Performance of Pharmacovigilance Signal‐Detection Algorithms for the FDA Adverse Event Reporting System , 2013, Clinical pharmacology and therapeutics.

[41]  Johan Hopstadius,et al.  Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery , 2011, Statistical methods in medical research.

[42]  Fabrizio De Ponti,et al.  Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS) , 2012 .

[43]  A. Bate,et al.  Quantitative signal detection using spontaneous ADR reporting , 2009, Pharmacoepidemiology and drug safety.

[44]  P. Mozzicato.  MedDRA: An Overview of the Medical Dictionary for Regulatory Activities , 2009 .

[45]  P. Mozzicato,et al.  Standardised MedDRA Queries , 2007, Drug safety.

[46]  A. Bate,et al.  A Bayesian neural network method for adverse drug reaction signal generation , 1998, European Journal of Clinical Pharmacology.

[47]  A. Nezu,et al.  American College of Physicians. , 1932, California and western medicine.